Pet liquid biopsy company, PetDx, will collaborate with IDEXX Laboratories, Inc. to grow access to canine cancer testing. PetDx’s liquid biopsy test, OncoK9, will be available to veterinary practices that utilize IDEXX across the US and Canada.
“We are excited about IDEXX's support of our noninvasive cancer testing solutions,” said Kalle Marsal, chief operating officer of PetDx. “Working closely with the industry leader will accelerate our efforts to equip the market with this breakthrough innovation, and ultimately benefit many dogs, their families, and the veterinarians that manage their care.”
Through the collaboration, PetDx will bring its molecular diagnostics to veterinary practices nationwide. The OncoK9 testing platform uses next-generation sequencing to find genomic alterations that are linked to canine cancer. The test liquid biopsy test was determined to detect cancer with a sensitivity similar on par with human genomic testing through the CANDiD study of more than 1000 dogs, according to the company.
List
Add
Please enter a comment